cloudfront
  • info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) | +1-214-736-7666 (US) | +1-740-994-0111 (US)
  • Sign In
  • Register

Pharma & Healthcare2018-2023 Global Performance Enhancing Drugs Consumption Market Report

  • RnM2475761
  • |
  • 29 August, 2018
  • |
  • Global
  • |
  • 133 pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Performance Enhancing Drugs market for 2018-2023.

Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.
A well-known example of PED involves doping in sport, where banned physical performance–enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
Over the next five years, LPI(LP Information) projects that Performance Enhancing Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Performance Enhancing Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:
Ergogenic Aids
Nootropic
Segmentation by application:
Athletes
Body Builders
Students
Militaries

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Taj Pharmaceuticals
Balkan Pharmaceuticals
Bayer
AstraZeneca
Novo Nordisk
BrainAlert
Douglas Laboratories
Onnit Labs
Eli Lilly And Company

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Performance Enhancing Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Performance Enhancing Drugs market by identifying its various subsegments.
Focuses on the key global Performance Enhancing Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Performance Enhancing Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Performance Enhancing Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.


Table of Contents

2018-2023 Global Performance Enhancing Drugs Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Performance Enhancing Drugs Consumption 2013-2023
2.1.2 Performance Enhancing Drugs Consumption CAGR by Region
2.2 Performance Enhancing Drugs Segment by Type
2.2.1 Ergogenic Aids
2.2.2 Nootropic
2.3 Performance Enhancing Drugs Consumption by Type
2.3.1 Global Performance Enhancing Drugs Consumption Market Share by Type (2013-2018)
2.3.2 Global Performance Enhancing Drugs Revenue and Market Share by Type (2013-2018)
2.3.3 Global Performance Enhancing Drugs Sale Price by Type (2013-2018)
2.4 Performance Enhancing Drugs Segment by Application
2.4.1 Athletes
2.4.2 Body Builders
2.4.3 Students
2.4.4 Militaries
2.5 Performance Enhancing Drugs Consumption by Application
2.5.1 Global Performance Enhancing Drugs Consumption Market Share by Application (2013-2018)
2.5.2 Global Performance Enhancing Drugs Value and Market Share by Application (2013-2018)
2.5.3 Global Performance Enhancing Drugs Sale Price by Application (2013-2018)

3 Global Performance Enhancing Drugs by Players
3.1 Global Performance Enhancing Drugs Sales Market Share by Players
3.1.1 Global Performance Enhancing Drugs Sales by Players (2016-2018)
3.1.2 Global Performance Enhancing Drugs Sales Market Share by Players (2016-2018)
3.2 Global Performance Enhancing Drugs Revenue Market Share by Players
3.2.1 Global Performance Enhancing Drugs Revenue by Players (2016-2018)
3.2.2 Global Performance Enhancing Drugs Revenue Market Share by Players (2016-2018)
3.3 Global Performance Enhancing Drugs Sale Price by Players
3.4 Global Performance Enhancing Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Performance Enhancing Drugs Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Performance Enhancing Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Performance Enhancing Drugs by Regions
4.1 Performance Enhancing Drugs by Regions
4.1.1 Global Performance Enhancing Drugs Consumption by Regions
4.1.2 Global Performance Enhancing Drugs Value by Regions
4.2 Americas Performance Enhancing Drugs Consumption Growth
4.3 APAC Performance Enhancing Drugs Consumption Growth
4.4 Europe Performance Enhancing Drugs Consumption Growth
4.5 Middle East & Africa Performance Enhancing Drugs Consumption Growth

5 Americas
5.1 Americas Performance Enhancing Drugs Consumption by Countries
5.1.1 Americas Performance Enhancing Drugs Consumption by Countries (2013-2018)
5.1.2 Americas Performance Enhancing Drugs Value by Countries (2013-2018)
5.2 Americas Performance Enhancing Drugs Consumption by Type
5.3 Americas Performance Enhancing Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Performance Enhancing Drugs Consumption by Countries
6.1.1 APAC Performance Enhancing Drugs Consumption by Countries (2013-2018)
6.1.2 APAC Performance Enhancing Drugs Value by Countries (2013-2018)
6.2 APAC Performance Enhancing Drugs Consumption by Type
6.3 APAC Performance Enhancing Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Performance Enhancing Drugs by Countries
7.1.1 Europe Performance Enhancing Drugs Consumption by Countries (2013-2018)
7.1.2 Europe Performance Enhancing Drugs Value by Countries (2013-2018)
7.2 Europe Performance Enhancing Drugs Consumption by Type
7.3 Europe Performance Enhancing Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Performance Enhancing Drugs by Countries
8.1.1 Middle East & Africa Performance Enhancing Drugs Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Performance Enhancing Drugs Value by Countries (2013-2018)
8.2 Middle East & Africa Performance Enhancing Drugs Consumption by Type
8.3 Middle East & Africa Performance Enhancing Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Performance Enhancing Drugs Distributors
10.3 Performance Enhancing Drugs Customer

11 Global Performance Enhancing Drugs Market Forecast
11.1 Global Performance Enhancing Drugs Consumption Forecast (2018-2023)
11.2 Global Performance Enhancing Drugs Forecast by Regions
11.2.1 Global Performance Enhancing Drugs Forecast by Regions (2018-2023)
11.2.2 Global Performance Enhancing Drugs Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Performance Enhancing Drugs Forecast by Type
11.8 Global Performance Enhancing Drugs Forecast by Application

12 Key Players Analysis
12.1 Taj Pharmaceuticals
12.1.1 Company Details
12.1.2 Performance Enhancing Drugs Product Offered
12.1.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Taj Pharmaceuticals News
12.2 Balkan Pharmaceuticals
12.2.1 Company Details
12.2.2 Performance Enhancing Drugs Product Offered
12.2.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Balkan Pharmaceuticals News
12.3 Bayer
12.3.1 Company Details
12.3.2 Performance Enhancing Drugs Product Offered
12.3.3 Bayer Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 Bayer News
12.4 AstraZeneca
12.4.1 Company Details
12.4.2 Performance Enhancing Drugs Product Offered
12.4.3 AstraZeneca Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 AstraZeneca News
12.5 Novo Nordisk
12.5.1 Company Details
12.5.2 Performance Enhancing Drugs Product Offered
12.5.3 Novo Nordisk Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 Novo Nordisk News
12.6 BrainAlert
12.6.1 Company Details
12.6.2 Performance Enhancing Drugs Product Offered
12.6.3 BrainAlert Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 BrainAlert News
12.7 Douglas Laboratories
12.7.1 Company Details
12.7.2 Performance Enhancing Drugs Product Offered
12.7.3 Douglas Laboratories Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Douglas Laboratories News
12.8 Onnit Labs
12.8.1 Company Details
12.8.2 Performance Enhancing Drugs Product Offered
12.8.3 Onnit Labs Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Onnit Labs News
12.9 Eli Lilly And Company
12.9.1 Company Details
12.9.2 Performance Enhancing Drugs Product Offered
12.9.3 Eli Lilly And Company Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 Eli Lilly And Company News

13 Research Findings and Conclusion


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Performance Enhancing Drugs . Industry analysis & Market Report on Performance Enhancing Drugs is a syndicated market report, published as 2018-2023 Global Performance Enhancing Drugs Consumption Market Report. It is complete Research Study and Industry Analysis of Performance Enhancing Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$4,660.00
$6,990.00
$9,320.00
3,129.19
4,693.79
6,258.38
4,288.13
6,432.20
8,576.26
564,512.40
846,768.60
1,129,024.80
309,020.44
463,530.67
618,040.89
Add To Cart Credit card Logo

Related Reports


Reason to Buy